Inspira Technologies FDA Listed, Market Ready New Product

Ticker: IINNW · Form: 6-K · Filed: Aug 22, 2024 · CIK: 1837493

Sentiment: bullish

Topics: FDA approval, new product, market readiness

TL;DR

FDA greenlights Inspira's new product, market launch imminent.

AI Summary

On August 22, 2024, Inspira Technologies Oxy B.H.N. Ltd. announced that its new product has been listed by the FDA and is ready for market. This marks a significant step for the company in the medical device sector.

Why It Matters

FDA listing signifies regulatory approval, paving the way for commercialization and potential revenue generation for Inspira's new medical device.

Risk Assessment

Risk Level: medium — While FDA listing is positive, market adoption and sales performance are yet to be determined, introducing commercial risks.

Key Players & Entities

FAQ

What is the specific name of the new product announced by Inspira Technologies?

The filing does not specify the name of the new product, only that it has received FDA listing and is market ready.

When was the press release announcing the FDA listing issued?

The press release was issued on August 22, 2024.

What is the Commission File Number for this filing?

The Commission File Number is 001-40303.

What is Inspira Technologies' principal executive office address?

The principal executive office is located at 2 Ha-Tidhar St. Ra'anana 4366504, Israel.

Does Inspira Technologies file annual reports under Form 20-F or 40-F?

Inspira Technologies files annual reports under Form 20-F.

Filing Stats: 301 words · 1 min read · ~1 pages · Grade level 8.7 · Accepted 2024-08-22 09:10:01

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Inspira Technologies Oxy B.H.N. Ltd. Date: August 22, 2024 By: /s/ Dagi Ben-Noon Name: Dagi Ben-Noon Title: Chief Executive Officer 2

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing